Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Stock Holdings Lowered by Virginia Retirement Systems ET AL
Virginia Retirement Systems ET AL lowered its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 24.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 25,700 shares of the specialty pharmaceutical company’s stock after selling 8,400 shares during the period. Virginia Retirement Systems ET AL’s holdings in Supernus Pharmaceuticals were worth $850,000 as of its most recent filing with the SEC.
Other institutional investors have also recently added to or reduced their stakes in the company. Financial Gravity Wealth Inc. bought a new position in shares of Supernus Pharmaceuticals during the first quarter worth about $44,000. Advisor Group Inc. grew its position in shares of Supernus Pharmaceuticals by 17.2% during the fourth quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 306 shares during the last quarter. Bremer Bank National Association bought a new position in Supernus Pharmaceuticals in the 1st quarter valued at about $94,000. Huntington National Bank grew its position in Supernus Pharmaceuticals by 881.4% in the 1st quarter. Huntington National Bank now owns 4,485 shares of the specialty pharmaceutical company’s stock valued at $157,000 after buying an additional 4,028 shares in the last quarter. Finally, Adams Diversified Equity Fund Inc. bought a new position in Supernus Pharmaceuticals in the 1st quarter valued at about $200,000. Institutional investors and hedge funds own 99.29% of the company’s stock.
A number of brokerages recently issued reports on SUPN. Cantor Fitzgerald set a $60.00 target price on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 8th. Stifel Nicolaus set a $55.00 target price on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 17th. Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Mizuho reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $54.43.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.05. Supernus Pharmaceuticals had a return on equity of 22.36% and a net margin of 25.66%. The firm had revenue of $104.70 million for the quarter, compared to the consensus estimate of $109.67 million. During the same quarter in the prior year, the company posted $0.57 earnings per share. The firm’s revenue was up 5.2% on a year-over-year basis. Equities research analysts anticipate that Supernus Pharmaceuticals Inc will post 2.2 earnings per share for the current fiscal year.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.